Predicting and overcoming resistance to CDK9 inhibitors for cancer therapy

Abnormally activated CDK9 participates in the super-enhancer mediated transcription of short-lived proteins required for cancer cell survival. Targeting CDK9 has shown potent anti-tumor activity in clinical trials among different cancers. However, the study and knowledge on drug resistance to CDK9 i...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Chen, Shen, Lijuan, Zou, Fengming, Wu, Yun, Wang, Beilei, Wang, Aoli, Wu, Chao, Wang, Li, Liu, Jing, Wang, Wenchao, Liu, Qingsong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502288/
https://www.ncbi.nlm.nih.gov/pubmed/37719386
http://dx.doi.org/10.1016/j.apsb.2023.05.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502288/
https://www.ncbi.nlm.nih.gov/pubmed/37719386
http://dx.doi.org/10.1016/j.apsb.2023.05.026

Ejemplares similares